4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Cerebral Palsy by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 118 ongoing clinical trials involving Cerebral Palsy
Of the 118 trials,44 trials are in Phase III
Furthermore, 25 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Cerebral Palsy by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Cerebral Palsy, acentral nervous system condition. Asia-Pacific, North America, and Europe are some of the prominent region sengaged in Cerebral Palsy-related drug trials.

Palsy related clinical trial sponsors

Jaslok Hospital & Research Centre, Teva Pharmaceutical Industries Ltd, Samara Regional Medical Center Dinasty, Amneal Pharmaceuticals Inc, and Ipsen SA are some of the notable clinical trial sponsors involved in Cerebral Palsy. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Cerebral Palsy

Onabotulinumtoxin A (Botox), Abobotulinumtoxin A (Dysport, Botulinum Toxin Type A, Azzalure), and Pyridostigmine Bromide (Mestinon) are among the key marketed drugs involving Cerebral Palsy.

Onabotulinumtoxin A (Botox) is a sterile, vacuum-dried purified botulinum toxin type A, produced from fermentation of Hall strain Clostridium botulinum type A. It functions via Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor mechanism of action. Onabotulinumtoxin A is formulated as injectable powder solution for intramuscular, subcutaneous and intradermal route of administration. Onabotulinumtoxin A is marketed for the treatment of Cerebral Palsy and several other indications including Migraine, Dystonia, Overactive Bladder, Neurogenic Bladder Dysfunction, Urinary Incontinence, Axillary Hyperhidrosis, Blepharospasm, Hemifacial Spasm, Lower Limb Muscle Spasticity, and Muscle Spasm. Onabotulinumtoxin A was first approved in 1991 and is marketed globally including the US, the UK, Australia, France, and Germany by several prominent pharma giants including AbbVie Inc, Allergan Sales LLC, and GlaxoSmithKline.

Abobotulinumtoxin A (Dysport, Botulinum Toxin Type A, Azzalure) is a neuromuscular blocking agent. It functions via Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor mechanism of action. Abobotulinumtoxin A is formulated as lyophilized powder for solution, solution for intramuscular and subcutaneous route of administration. Abobotulinumtoxin A is marketed for the treatment of Cerebral Palsy and several other indications including Axillary Hyperhidrosis, Blepharospasm, Hemifacial Spasm, Lower Limb Muscle Spasticity, Muscle Spasm, Muscle Spasticity, Spasmodic Torticollis (Cervical Dystonia), Torticollis, and Upper Limb Muscle Spasticity. Abobotulinumtoxin A was first approved in 1990 and is marketed globally including the US, the UK, Australia, France, and Germany by several prominent pharma giants including Abacus Medicine A/S, EurimPharm Arzneimittel GmbH, and Ipsen SA.